NLRP3 Knockout cell line(THP-1)

Catalog Number: KO00842

Specifications KO Solutions KO Cell Line Workflow Handling procedures Downloads Related products

Specifications

Product Information
Product Name	NLRP3 Knockout cell line(THP-1)
specification	1*10^6
Storage and transportation	Dry ice preservation/T25 live cell transportation.
Cell morphology	Monocytes, suspended growth
Passage ratio	1：2-1：4
species	Human
Gene	NLRP3
Gene ID	114548
Build method	Electric rotation method / virus method
Mycoplasma testing	Negative
Cultivation system	90%RPMI-1640+10%FBS
Parental Cell Line	THP-1
Quality Control	Genotype: NLRP3 Knockout cell line(THP-1) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins.

Gene Information
Gene Official Full Name	NLR family pyrin domain containing 3provided by HGNC
Also known as	AII; AVP; FCU; MWS; FCAS; KEFH; CIAS1; FCAS1; NALP3; C1orf7; CLR1.1; DFNA34; PYPAF1; AGTAVPRL
Gene Description	This gene encodes a pyrin-like protein containing a pyrin domain, a nucleotide-binding site (NBS) domain, and a leucine-rich repeat (LRR) motif. This protein interacts with the apoptosis-associated speck-like protein PYCARD/ASC, which contains a caspase recruitment domain, and is a member of the NLRP3 inflammasome complex. This complex functions as an upstream activator of NF-kappaB signaling, and it plays a role in the regulation of inflammation, the immune response, and apoptosis. The SARS-CoV 3a protein, a transmembrane pore-forming viroporin, has been shown to activate the NLRP3 inflammasome via the formation of ion channels in macrophages. Mutations in this gene are associated with familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous and articular (CINCA) syndrome, neonatal-onset multisystem inflammatory disease (NOMID), keratoendotheliitis fugax hereditarian, and deafness, autosomal dominant 34, with or without inflammation. Multiple alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. Alternative 5' UTR structures are suggested by available data; however, insufficient evidence is available to determine if all of the represented 5' UTR splice patterns are biologically valid. [provided by RefSeq, Aug 2020]
Expression	Biased expression in bone marrow (RPKM 20.0), appendix (RPKM 6.0) and 9 other tissues See more

KO Solutions

We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.

Editing Tools

Cas9 Protein

Cas9 mRNA sgRNA

Cas9 Plasmid

Cas9 Virus

A – Exon KO

gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.

B - Frameshift KO

gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.

C - Complete KO

The entire gene coding sequence is deleted, achieving large-scale knockout effects.

KO Cell Line Workflow

KO Strategy Design

CRISPR Plasmid/Lentiviral Vector Construction

Lentiviral Packaging

Cell Transfection/Lentiviral Infection

Drug Selection

Cell Cryopreservation

Quality Control

Sequencing Validation

Monoclonal Cell Line Generation

Pool Efficiency Validation

Handling procedures

Cell Thawing

Pre-warm complete culture medium in a 37°C water bath.
Thaw the cryovial in a 37°C water bath for 1–2 minutes.
Transfer the cryovial to a biosafety cabinet (BSC) and wipe the surface with 70% ethanol.
Loosen the cap and gently transfer the cell suspension into a sterile centrifuge tube containing 9 mL of complete medium.
Centrifuge at 125 × g for 5–7 min at room temperature (RT), then discard the supernatant.
Resuspend the cell pellet in 5 mL of complete medium and transfer the suspension into a T25 flask.
Incubate the cells at 37°C in a 5% CO₂ incubator.
Recommended subculturing ratio: 1:2 to 1:3, reaching confluency in 2–3 days.

Cell Passaging

When cell confluence reaches 80–90%, proceed with passaging.
Pre-warm complete medium, PBS, and trypsin (0.25% Trypsin-EDTA, Gibco 25200-056) in a 37°C water bath. Once near 37°C, spray the bottles with 75% ethanol and place them in the BSC.
Retrieve the culture flask from the incubator, spray with 75% ethanol, and transfer it to the BSC.
To avoid dislodging cells, gently rinse the monolayer with PBS along the upper wall of the flask. Discard the PBS after washing (use 2 mL for T25 flasks).
Add an appropriate volume of trypsin (1.5 mL for T75, 0.5 mL for T25) and gently tilt the flask to ensure full coverage. Adjust the volume as needed. After 1–2 min, when most cells detach, neutralize digestion by adding an equal volume of complete medium. Gently pipette with a 5 mL serological pipette to ensure complete detachment.
Transfer the cell suspension to a 15 mL centrifuge tube and spin at 300 × g for 5 min. Discard the supernatant.
Resuspend the pellet in 5 mL of complete medium, adjust the seeding ratio as required, and replenish the flask with fresh medium (13–15 mL for T75, 5 mL for T25). Add 1% penicillin-streptomycin (dual antibiotic).
Tighten the cap, gently swirl to mix, and place the flask in a 37°C, 5% CO₂ incubator.

Cell Cryopreservation

Prepare cryopreservation medium in advance and pre-chill.
Ensure cells meet freezing criteria: healthy morphology, late-log phase growth, and absence of contamination or senescence (verify under a microscope).
Digest and centrifuge the cells (refer to the passaging protocol).
Resuspend the cell pellet in cryopreservation medium (1 mL per vial), mix thoroughly, and aliquot into cryovials.
Place the vials in a freezing container and store at −80°C overnight.
For long-term storage, transfer the cryovials to a liquid nitrogen tank.

Downloads

Datasheet

Please note that all services are for research use only. Not intended for any clinical use.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.